Inventor
LE KANG
US25 patents
⚠️ This page may combine multiple inventors who share the name “LE KANG”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV TEXAS
17 patentsUS10344025B2Jul 9, 2019
GLS1 inhibitors for treating disease
UNIV TEXAS12 citations91
US9809588B2Nov 7, 2017
GLS1 inhibitors for treating disease
UNIV TEXAS15 citations91
US11603365B2Mar 14, 2023
Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1H-1,2,3-triazole-4-carboxamide
UNIV TEXAS4 citations85
US11370786B2Jun 28, 2022
GLS1 inhibitors for treating disease
UNIV TEXAS6 citations84
US10899740B2Jan 26, 2021
Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido)pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide
UNIV TEXAS8 citations84
US10150753B2Dec 11, 2018
Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyrdin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide
UNIV TEXAS7 citations84
US10766892B2Sep 8, 2020
GLS1 inhibitors for treating disease
UNIV TEXAS9 citations83
US10093664B2Oct 9, 2018
Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
UNIV TEXAS4 citations73
US12186324B2Jan 7, 2025
Imidazopiperazine inhibitors of transcription activating proteins
UNIV TEXAS3 citations72
US11958849B2Apr 16, 2024
GLS1 inhibitors for treating disease
UNIV TEXAS2 citations72
US10899769B2Jan 26, 2021
Imidazopiperazinone inhibitors of transcription activating proteins
UNIV TEXAS3 citations72
US11058688B2Jul 13, 2021
Imidazopiperazine inhibitors of transcription activating proteins
UNIV TEXAS3 citations71
US12252480B2Mar 18, 2025
Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1H-1,2,3-triazole-4-carboxamide
UNIV TEXAS0 citations62
US11560366B2Jan 24, 2023
Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
UNIV TEXAS1 citations62
US10428057B2Oct 1, 2019
Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
UNIV TEXAS1 citations62
US12559497B2Feb 24, 2026
Imidazopiperazine inhibitors of transcription activating proteins
UNIV TEXAS0 citations61
US12540139B2Feb 3, 2026
Imidazopiperazine inhibitors of transcription activating proteins
UNIV TEXAS0 citations61
HOFFMANN LA ROCHE
8 patentsUS6784298B2Aug 31, 2004
Hydantoin-containing glucokinase activators
HOFFMANN LA ROCHE28 citations92
US6583288B2Jun 24, 2003
Hydantoin-containing glucokinase activators
HOFFMANN LA ROCHE29 citations92
US7504513B2Mar 17, 2009
Thiazolyl-benzimidazoles
HOFFMANN LA ROCHE13 citations83
US7645773B2Jan 12, 2010
Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase
HOFFMANN LA ROCHE6 citations62
US9422332B2Aug 23, 2016
Azaheterocycles as BIR2 and/or BIR3 inhibitors
HOFFMANN LA ROCHE0 citations51
US8044213B2Oct 25, 2011
Thiazolyl-benzimidazoles
HOFFMANN LA ROCHE0 citations41
US9394263B2Jul 19, 2016
Substituted hetero-azepinones
HOFFMANN LA ROCHE0 citations39
US10053431B2Aug 21, 2018
Tetrahydro-benzodiazepinones
HOFFMANN LA ROCHE0 citations38